Evidence map›Paper›PMID 38090523›Full record

ArticleTranslational lung cancer research2023

Real-world first-line afatinib for advanced

Juwhan Choi, Chang Min Choi, Yoon Soo Chang, Kye Young Lee, Seung Joon Kim, Sei Hoon Yang, Jeong Seon Ryu, Jeong Eun Lee, Shin Yup Lee, Ji Young Park and 7 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. J-REGISTER: real-world study of Japanese patients withFuture oncology (London, England) · 2025
    Observational
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 1 country.

Juwhan ChoiDivision of Pulmonary, Department of Internal Medicine, Korea University Guro Hospital, Seoul, South Korea.
Chang Min ChoiDepartment of Pulmonary and Critical Care Medicine, Ulsan University Asan Medical Center, Seoul, South Korea.
Yoon Soo ChangDivision of Pulmonary, Department of Internal Medicine, Yonsei University Gangnam Severance Hospital, Seoul, South Korea.
Kye Young LeePrecision Medicine Lung Cancer Center, Konkuk University Medical Center, Seoul, South Korea.
Seung Joon KimDivision of Pulmonary, Department of Internal Medicine, Catholic University Seoul St. Mary's Hospital, Seoul, South Korea.
Sei Hoon YangDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Wonkwang University Hospital, Iksan, South Korea.
Jeong Seon RyuDivision of Pulmonary, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea.
Jeong Eun LeeDivision of Pulmonary, Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea.
Shin Yup LeeDivision of Pulmonary, Department of Internal Medicine, Kyungpook National University, Daegu, South Korea.
Ji Young ParkDivision of Pulmonary, Allergy and Critical Medicine, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, South Korea.
Young-Chul KimDepartment of Internal Medicine, Chonnam National University Medical School and Hwasun Hospital, Hwasun, South Korea.
In-Jae OhDepartment of Internal Medicine, Chonnam National University Medical School and Hwasun Hospital, Hwasun, South Korea.
Chi Young JungDivision of Pulmonary, Department of Internal Medicine, Daegu Catholic University Medical Center, Daegu, South Korea.
Sang Hoon LeeDivision of Pulmonary, Department of Internal Medicine, Yonsei University Severance Hospital, Seoul, South Korea.
Seong Hoon YoonDivision of Pulmonary, Department of Internal Medicine, Pusan National University Yangsan Hospital, Yangsan, South Korea.
Sung Yong LeeDivision of Pulmonary, Department of Internal Medicine, Korea University Guro Hospital, Seoul, South Korea.
Tae Won JangDivision of Pulmonary, Department of Internal Medicine, Kosin University Gospel Hospital, Busan, South Korea.
Korea University Medical Center · KRAsan Medical Center · KRThe Catholic University of Korea Seoul St. Mary's Hospital · KRChonnam National University Hwasun Hospital · KRChungnam National University Hospital · KRGangnam Severance Hospital · KRInha University Hospital · KRKonkuk University Medical Center · KRKyungpook National University · KRWonkwang University · KRYonsei University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Data from clinical trials and real-world studies show that afatinib is effective in treating non-small cell lung cancer (NSCLC) harboring activating mutations in the epidermal growth factor receptor ( Methods: The study was a retrospective, multicenter (15 sites) review of electronic records of Korean adult patients (aged >20 years) with advanced Results: Overall, median PFS was 20.2 months and median OS was 48.6 months. OS rates at 36 and 60 months were 60.1% and 42.3%, respectively. Presence Conclusions: Afatinib was effective in Korean patients with

Indexed as

Afatinibepidermal growth factor receptor (EGFR)first-linenon-small cell lung cancer (NSCLC)real-world

Identifiers

PMID38090523
PMCPMC10713275
OpenAlexW4389110069

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.